Fotemustine
Muphoran · Nitrosourea (alkylating)
Class delayed cumulative tubulointerstitial/ATN; usually mild; acute signal often really cisplatin.
Pluvicto · LUPS
Radioligand therapy (PSMA) · approved 2022 · 12 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A PSMA-targeted beta-emitter for prostate cancer whose kidney is the highest-dose internal organ — though the salivary glands usually steal the spotlight.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Clinically significant nephrotoxicity is uncommon in trial populations and is not well quantified; in VISION renal adverse events were infrequent. Dosimetry consistently shows the kidney is the highest-dose internal organ, but the dose-limiting clinical toxicities are usually xerostomia (salivary/lacrimal uptake) and myelosuppression rather than renal failure. Reported rate: grade >=3 ctcae nephrotoxicity worsening to grade 3 in 9.4% — 32 consecutive heavily pre-treated mCRPC patients selected by 68Ga-PSMA-11 PET/CT and given 177Lu-PSMA-617 monotherapy… (Maffey-Steffan 2020, PMID 31776632).Source: Maffey-Steffan et al., Eur J Nucl Med Mol Imaging 2020
Renal changes are delayed/gradual; xerostomia can appear early.
Distilled from: “Renal changes are delayed/gradual; xerostomia can appear early during treatment.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Slow, cumulative tubulointerstitial scarring — fibrosis, tubular atrophy and glomerulosclerosis with no discrete acute phase. The nitrosourea (carmustine/lomustine) lesion and delayed radioligand (radiation) nephropathy; often irreversible and detected only as a creeping creatinine months to years later.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Representative grade ≥3 incidence
Chronic Interstitial Nephropathy strikes: Interstitium.
Chronic Interstitial Nephropathy
Slow, cumulative tubulointerstitial scarring — fibrosis, tubular atrophy and glomerulosclerosis with no discrete acute phase. The nitrosourea (carmustine/lomustine) lesion and delayed radioligand (radiation) nephropathy; often irreversible and detected only as a creeping creatinine months to years later.
Beta-emitting lutetium-177 conjugated to a small-molecule ligand (PSMA-617 / vipivotide tetraxetan) that binds prostate-specific membrane antigen (PSMA, glutamate carboxypeptidase II) overexpressed on prostate-cancer cells. After binding and internalization, targeted beta radiation produces lethal DNA damage.
11 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Non-PubMed sources — conference abstracts (e.g. ASN Kidney Week, badged Abstract) and case reports from non-indexed field journals (e.g. Journal of Onco-Nephrology, badged Journal). Included for completeness; weigh below peer-reviewed PubMed citations.
Quoted verbatim from this agent's current FDA label (Aug 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Exposure of lutetium Lu 177 vipivotide tetraxetan is expected to increase with the degree of renal impairment [see Clinical Pharmacology (12.3)] . No dose adjustment is recommended for patients with mild (baseline CLcr 60 to 89 mL/min by Cockcroft-Gault) to moderate (CLcr 30 to 59 mL/min) renal impairment; however, patients with mild to moderate renal impairment may be at greater risk of toxicity. Frequently monitor renal function and adverse reactions in patients with mild to moderate renal impairment [see Dosage and Administration (2.4)] . The pharmacokinetics and safety of PLUVICTO have not been studied in patients with severe (CLcr 15 to 29 mL/min) renal impairment or end-stage renal disease.
Kidney rows of the label's dosage tables
From the PLUVICTO label (Aug 2026) · DailyMed
The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. Educational only, not medical advice.
| Renal toxicity [see Warnings and Precautions (5.3)] | Defined as: Confirmed serum creatinine increase (Grade ≥ 2) Confirmed CLcr < 30 mL/min; calculate using Cockcroft-Gault with actual body weight | Withhold PLUVICTO until improvement. |
3 more rows naming a kidney term and an action are left out, because they could not be reproduced without guessing (a merged or blank cell, an image, or a footnote inside the text). The full table on DailyMed has them.
Everything below is FAERS — adverse events someone chose to report, about 13,841 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Reported with a death outcome
1,680 of 13,841 reports
Reported with hospitalization
725 of 13,841 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Lutetium-177 PSMA-617 (vipivotide) sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Muphoran · Nitrosourea (alkylating)
Class delayed cumulative tubulointerstitial/ATN; usually mild; acute signal often really cisplatin.
Nidran · Nitrosourea (alkylating)
Water-soluble nitrosourea; renal risk inferred at class level; cumulative delayed tubulointerstitial injury; DLT is myelosuppression.
Zelboraf · BRAF inhibitor
Strongest renal offender of the BRAF/MEK class: proximal tubular injury/Fanconi and early AKI.
Alimta · Antifolate
Cumulative chronic tubulointerstitial injury; RTA and nephrogenic DI.
Lutathera · Radioligand therapy (PRRT)
Peptide receptor radionuclide therapy; proximal tubular radiation nephropathy is dose-limiting — amino-acid co-infusion is renoprotective.
Balversa · FGFR inhibitor
Hyperphosphatemia is an on-target class effect.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.